ThinkstockViroPharma Inc. (NASDAQ: VPHM) has become the latest and greatest biotech buyout candidate after a report of it being a buyout candidate surfaced last week. We saw some 11 million shares trade hands on…
ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the population. From obesity to food allergies to prostate cancer, the top companies often try…
ThinkstockJohnson & Johnson (NYSE: JNJ) has been one of the great health care and consumer products survivors of our lifetimes. Even the latest round of over-the-counter quality control flaws did not cripple the great…
ThinkstockAn estimated 14.5 million American households had difficulty providing enough food for their families last year, according to a recent government report. In 7 million of those homes, at least one member of the…
ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their recent report that the U.S. downgrade…
Any time you see a merger announcement, you see a myriad of press releases pertaining to law firms and lawyers investigating the terms of the deal. This is in one sense the new form…
ThinkstockAmgen Inc. (NASDAQ: AMGN) wants to regain its status as the largest publicly traded biotech in the U.S. The company formalized a buyout of cancer drug maker Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) for about $10.4 billion…
ThinkstockIt appears that scam artists are now targeting medical marijuana and legalized marijuana schemes to part you from your money. As the business opportunities are rising around the new and controversial field of legalized…
ThinkstockMerck & Co. Inc. (NYSE: MRK) is seeing one more drug drive off the patent cliff. News was released on Monday by Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) that it and Perrigo Co. (NYSE: PRGO)…
ThinkstockWhen short interest, or the amount of any specific stock sold short, starts to decline, that is usually a flashing sign for investors to take a look behind the curtain. In general, a lower…
Opexa Therapeutics Inc. (NASDAQ: OPXA) may have just become the villain of Wall Street in emerging pharma and biotech. This stock more than doubled on Wednesday, on what was no official news but around…
ThinkstockThe war against Alzheimer’s disease is getting another round of stem cell research thrown at it. While this involves a public company, the reality is that Alzheimer’s is truly a holy grail for any…
ThinkstockSequenom Inc. (NASDAQ: SQNM) is back in the news, but not in a good way. The company that saw its share price collapse in 2009 over its genetic test kits not doing what they…
ThinkstockHeart disease, which causes heart attacks, is the leading cause of death in the United States. More than 700,000 Americans have a heart attack each year. According to the Gallup-Healthways annual well-being study, some U.S.…
ThinkstockTypically, specialty pharmaceutical companies either provide generic versions of former top-selling branded drugs or they may focus on drugs that target rare or hard to treat diseases as orphan drug manufacturers. One thing is…